Literature DB >> 21512137

c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.

Jens Rauch1, Kim Moran-Jones, Valerie Albrecht, Thomas Schwarzl, Keith Hunter, Olivier Gires, Walter Kolch.   

Abstract

A-Raf kinase can inhibit apoptosis by binding to the proapoptotic mammalian sterile 20-like kinase (MST2). This function relies on expression of hnRNP H, which ensures the correct splicing of a-raf mRNA needed to produce full-length A-Raf protein. Here, we showed that expression of hnRNP H and production of full-length A-Raf is positively controlled by c-Myc. Low c-Myc reduces hnRNP H expression and switches a-raf splicing to produce A-Raf(short), a truncated protein. Importantly, A-Raf(short) fails to regulate MST2 but retains the Ras-binding domain such that it functions as a dominant negative mutant suppressing Ras activation and transformation. Human colon and head and neck cancers exhibit high hnRNP H and high c-Myc levels resulting in enhanced A-Raf expression and reduced expression of A-Raf(short). Conversely, in normal cells and tissues in which c-Myc and hnRNP H are low, A-Raf(short) suppresses extracellular signal regulated kinase activation such that it may act as a safeguard against oncogenic transformation. Our findings offered a new paradigm to understand how c-Myc coordinates diverse cell functions by directly affecting alternate splicing of key signaling components. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512137      PMCID: PMC3130132          DOI: 10.1158/0008-5472.CAN-10-4447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

2.  Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation.

Authors:  David Matallanas; Victoria Sanz-Moreno; Imanol Arozarena; Fernando Calvo; Lorena Agudo-Ibáñez; Eugenio Santos; María T Berciano; Piero Crespo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 3.  The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression.

Authors:  Brian Carpenter; Catriona MacKay; Ayham Alnabulsi; Morven MacKay; Colin Telfer; William T Melvin; Graeme I Murray
Journal:  Biochim Biophys Acta       Date:  2005-11-15

Review 4.  Messenger RNA surveillance: neutralizing natural nonsense.

Authors:  Joachim Weischenfeldt; Jens Lykke-Andersen; Bo Porse
Journal:  Curr Biol       Date:  2005-07-26       Impact factor: 10.834

5.  Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression.

Authors:  Qun Pan; Arneet L Saltzman; Yoon Ki Kim; Christine Misquitta; Ofer Shai; Lynne E Maquat; Brendan J Frey; Benjamin J Blencowe
Journal:  Genes Dev       Date:  2006-01-15       Impact factor: 11.361

Review 6.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

7.  Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.

Authors:  Anna Mayer; Michaela Andratschke; Christof Pauli; Hendrik Graefe; Kolbow Kristina; Barbara Wollenberg
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

8.  Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x.

Authors:  Daniel Garneau; Timothée Revil; Jean-François Fisette; Benoit Chabot
Journal:  J Biol Chem       Date:  2005-04-18       Impact factor: 5.157

9.  Retroviral expression screening of oncogenes in pancreatic ductal carcinoma.

Authors:  Hiroyuki Kisanuki; Young Lim Choi; Tomoaki Wada; Ryozo Moriuchi; Shin-Ichiro Fujiwara; Ruri Kaneda; Koji Koinuma; Madoka Ishikawa; Shuji Takada; Yoshihiro Yamashita; Hiroyuki Mano
Journal:  Eur J Cancer       Date:  2005-09       Impact factor: 9.162

Review 10.  Unbalanced alternative splicing and its significance in cancer.

Authors:  Julian P Venables
Journal:  Bioessays       Date:  2006-04       Impact factor: 4.345

View more
  29 in total

Review 1.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

2.  Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Jian-Xiong Huang; Jian Wu; Guang Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Structure-Mediated RNA Decay by UPF1 and G3BP1.

Authors:  Joseph W Fischer; Veronica F Busa; Yue Shao; Anthony K L Leung
Journal:  Mol Cell       Date:  2020-02-03       Impact factor: 17.970

4.  Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.

Authors:  Amrita Datta; Hogyoung Kim; Madhu Lal; Lauren McGee; Adedoyin Johnson; Ahmed A Moustafa; Jennifer C Jones; Debasis Mondal; Marc Ferrer; Asim B Abdel-Mageed
Journal:  Cancer Lett       Date:  2017-08-24       Impact factor: 8.679

5.  Spatial regulation of ARAF controls the MST2-Hippo pathway.

Authors:  Jens Rauch; Walter Kolch
Journal:  Small GTPases       Date:  2017-03-10

6.  A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation.

Authors:  Xinjian Li; Xu Qian; Li-Xia Peng; Yuhui Jiang; David H Hawke; Yanhua Zheng; Yan Xia; Jong-Ho Lee; Gilbert Cote; Hongxia Wang; Liwei Wang; Chao-Nan Qian; Zhimin Lu
Journal:  Nat Cell Biol       Date:  2016-04-18       Impact factor: 28.824

Review 7.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

8.  Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC.

Authors:  Shipra Das; Olga Anczuków; Martin Akerman; Adrian R Krainer
Journal:  Cell Rep       Date:  2012-02-23       Impact factor: 9.423

9.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

10.  Nuclear localized Raf1 isoform alters DNA-dependent protein kinase activity and the DNA damage response.

Authors:  Benjamin R Nixon; Sara C Sebag; Michael S Glennon; Eric J Hall; Emily S Kounlavong; Michael L Freeman; Jason R Becker
Journal:  FASEB J       Date:  2018-08-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.